Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HQP1351 in refractory CML and Ph+ ALL
NCT04260022Phase 1Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Jan 2020
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of olverembatinib in chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (4 cohorts), sponsored by Ascentage Pharma. Primary endpoints: Maximum Plasma Concentration of HQP1351 at 28 days and Area Under the Curve of HQP1351 at 28 days. Started Jan 2020; status: recruiting.
02
Drugs
olverembatinib
03
Conditions
chronic myeloid leukemia (CML)Philadelphia-chromosome positive acute lymphoblastic leukemia
Beyond the preview
Go deeper on NCT04260022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04260022.